UCB buffs up in block­buster pso­ri­a­sis race as bimek­izum­ab beats Hu­mi­ra in head-to-head

Just weeks af­ter boast­ing head-to-head vic­to­ries over first place­bo and then J&J’s IL-23 con­tender Ste­lara in clear­ing pso­ri­a­sis, the re­sults are in for UCB’s last Phase III tri­al, in which bimek­izum­ab went up against the world’s best-sell­ing drug.

On­ly topline re­sults are pro­vid­ed for to­day’s read­out of the BE SURE study, so we won’t find out just how su­pe­ri­or bimek­izum­ab proved against Hu­mi­ra on the co-pri­ma­ry end­points — stan­dard scores known as PASI90 and IGA mea­sur­ing the im­pact and sever­i­ty of the dis­ease — un­til a sci­en­tif­ic con­fer­ence in 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER